コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 measured by the incidence of POE and cystoid macular edema.
2 age-related macular degeneration or diabetic macular edema.
3 reated with Dexamethasone implant 0.7 mg for macular edema.
4 eration, retinal vein occlusion and diabetic macular edema.
5 of spreading capillary loss with associated macular edema.
6 macotherapy for treatment of CRVO-associated macular edema.
7 er factors is an important cause of diabetic macular edema.
8 to treatment in severely affected eyes with macular edema.
9 illary nonperfusion in eyes without diabetic macular edema.
10 71 (38) microm in the 7 exposed eyes without macular edema.
11 age-related macular degeneration or diabetic macular edema.
12 e largest increases at the time of recurrent macular edema.
13 ce of proliferative diabetic retinopathy and macular edema.
14 ce of proliferative diabetic retinopathy and macular edema.
15 graphs gradable for diabetic retinopathy and macular edema.
16 growth factor for the treatment of diabetic macular edema.
17 betic retinopathy in the absence of diabetic macular edema.
18 75%) had visual acuity of 20/70 or worse and macular edema.
19 cause ocular adverse effects such as cystoid macular edema.
20 possibly independent indicators of recurrent macular edema.
21 ns during 6 months in patients with diabetic macular edema.
22 apy, as initial treatment for RVO-associated macular edema.
23 with a greater likelihood of improvement in macular edema.
24 VO and HRVO patients receiving treatment for macular edema.
25 nable-to-determine result for retinopathy or macular edema.
26 y may prevent the postoperative worsening of macular edema.
27 ntral macula with or without typical cystoid macular edema.
28 r leakage observed in patients with diabetic macular edema.
29 l coherence tomography detection of diabetic macular edema.
30 retinopathy (DR) in the absence of diabetic macular edema.
31 age-related macular degeneration or diabetic macular edema.
32 increased vascular permeability in diabetic macular edema.
33 ly lower in the DRL of subjects with uveitic macular edema.
35 Primary outcome measure was resolution of macular edema 1 month after injection as measured by dec
36 and serum samples of patients with diabetic macular edema (1.6-fold) measured by Western blot and EL
37 retained cortical fragment (1 [4%]), cystoid macular edema (2 [8%]), and IOL subluxation (3 [13%]) ow
38 ncidence of proliferative retinopathy and of macular edema, 2 important causes of visual impairment i
39 ferative diabetic retinopathy (NPDR) without macular edema, 20 eyes had proliferative diabetic retino
40 309 (78) microm in the 6 eyes with diagnosed macular edema, 279 (23) microm in the fellow eyes, and 2
41 f 124 eyes analyzed, 60 (48.4%) had diabetic macular edema, 32 (25.8%) had neovascular age-related ma
43 rticipants; 95% CI, 36.6%-39.4%) followed by macular edema (7% of participants; 95% CI, 6.3%-7.7%).
45 retinal vascular permeability contributes to macular edema, a leading cause of vision loss in eye pat
46 tacle-corrected visual acuity, resolution of macular edema, adverse events, subgroup analysis by anat
52 mized trial data on 660 adults with diabetic macular edema and decreased VA (Snellen equivalent, appr
53 of 9 mg/0.1 mL was associated with transient macular edema and diminished visual acuity in 6 of 13 ex
55 ne acetonide (IVTA) is effective at reducing macular edema and improving visual acuity in participant
57 participants) with center-involved diabetic macular edema and no preexisting open-angle glaucoma, 26
61 ing the search terms diabetic retinopathy OR macular edema AND stroke OR cerebrovascular disease OR c
62 having diabetic retinopathy without diabetic macular edema and underwent fluorescein angiography and
64 ibercept Injection in Patients With Diabetic Macular Edema) and VIVID (Intravitreal Aflibercept Injec
65 ibercept Injection in Patients With Diabetic Macular Edema) and VIVID (Intravitreal Aflibercept Injec
66 iferative diabetic retinopathy (PDR) without macular edema, and 27 eyes had diabetic macular edema (D
67 retinal disease, including uveitis, diabetic macular edema, and age-related macular degeneration.
69 o 7 times for diabetic retinopathy, diabetic macular edema, and image gradability by a panel of 54 US
70 The improvement in VA, anatomic reduction of macular edema, and improvement in DR severity score with
71 change, proportion of patients with resolved macular edema, and leakage on fluorescein angiography.
72 diabetic retinopathy, clinically significant macular edema, and the need for intervention (photocoagu
75 ative diabetic retinopathy, and incidence of macular edema as assessed via grading of color stereo fi
76 f nonproliferative DR, proliferative DR, and macular edema, as well as stereoscopic fundus photograph
77 reatment of decreased vision attributable to macular edema associated with central retinal vein occlu
78 degradable implant approved for treatment of macular edema associated with retinal vein occlusion (RV
79 lateral synechiae, bilateral papilledema and macular edema associated with serous retinal detachment
81 50%) compared with eyes without subclinical macular edema at baseline (n = 39; 30%) (P = 0.005; haza
82 nalysis, factors associated with subclinical macular edema at baseline were increasing tumor diameter
83 affected by uveitis, even in the presence of macular edema, at least in the early stage of the inflam
84 xudative age-related macular degeneration or macular edema attributable to retinal vein occlusion.
85 -VEGF treatment, but longer mean duration of macular edema before randomization (18 months vs. 1 mont
86 rative retinopathy or clinically significant macular edema, both of which require timely intervention
87 vision in eyes with center-involved diabetic macular edema, but the relative effect depended on basel
89 trast to the rapid effects of ranibizumab on macular edema, changes in HE area were more gradual.
90 for uveal melanoma demonstrated OCT-evident macular edema, clinically evident radiation maculopathy,
95 y (VA), complications, resolution of cystoid macular edema (CME), and anterior chamber and vitreous i
96 ersistent fetal foveal architecture, cystoid macular edema (CME), intraretinal exudates and subretina
98 ar pressure (IOP) increase (n = 12), cystoid macular edema (CME; n = 3), and nonarteritic anterior is
99 ETDRS] of 55 letters or better); (2) cystoid macular edema (CMO), foveal thickness, and macular volum
102 ved over time such that the proportions with macular edema converged in the 2 groups by 36 months and
103 nce of DME, including clinically significant macular edema (CSME), on monocular fundus photographs us
106 oliferative DR [PDR], clinically significant macular edema [CSME], or both who had evidence of retina
107 Patients with neovascular AMD and persistent macular edema despite fixed-interval intravitreous anti-
109 d hyperemia and swelling of the optic nerve, macular edema, diffuse intraretinal hemorrhages, and dil
110 tinopathy (n = 9) and patients with diabetic macular edema (DME) (n = 31) were compared with healthy
111 0.7) was approved for treatment of diabetic macular edema (DME) after demonstration of its efficacy
114 d characterization of patients with diabetic macular edema (DME) are important for individualizing tr
115 (VA 20/32 or worse) center-involved diabetic macular edema (DME) at baseline were required to receive
116 a shorter duration of diabetes and diabetic macular edema (DME) at baseline, were less likely to hav
117 l aflibercept injections (IAIs) for diabetic macular edema (DME) during the phase III VISTA DME trial
118 owth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic retinopat
120 nibizumab (0.3 mg) for treatment of diabetic macular edema (DME) involving the center of the retina a
121 al dexamethasone implant therapy in diabetic macular edema (DME) is associated with long-term outcome
123 t, bevacizumab, and ranibizumab for diabetic macular edema (DME) might influence interpretation of st
124 potential effect of treatments for diabetic macular edema (DME) on driving should be of value to pat
125 pro-permeability factors (PPFs) in diabetic macular edema (DME) patients before and after injection
126 ic fundus photographs, we evaluated diabetic macular edema (DME) progression and DR progression.
127 thly dosing period) (2q8) and other diabetic macular edema (DME) therapies at doses licensed outside
128 sham in the first-line treatment of diabetic macular edema (DME) to inform technology assessments suc
129 erity score (DRSS) in patients with diabetic macular edema (DME) treated with intravitreal ranibizuma
133 tional characteristics in eyes with diabetic macular edema (DME) with subfoveal neuroretinal detachme
134 growth factor therapy in eyes with diabetic macular edema (DME) with vision loss after macular laser
135 growth factor therapy in eyes with diabetic macular edema (DME) with vision loss after macular laser
136 erative DR (NPDR), 51 with NPDR and diabetic macular edema (DME), and 18 with proliferative DR (PDR)-
137 Retinal hypoxia also contributes to diabetic macular edema (DME), and because of the absence of good
138 related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) we
139 related macular degeneration (AMD), diabetic macular edema (DME), central and branch retinal vein occ
140 kening of the center of the retina, diabetic macular edema (DME), is the most common cause of visual
141 herapeutic target for patients with diabetic macular edema (DME), perhaps in combination with current
142 elated macular degeneration (nAMD), diabetic macular edema (DME), retinal vein occlusion, choroidal n
155 ated macular degeneration (AMD) and diabetic macular edema (DME).All patients were operated at a smal
156 acular degeneration (AMD, n = 400), diabetic macular edema (DME, n = 400), or retinal vein occlusion
157 2 diabetes and severe stages of DR (diabetic macular edema [DME] and proliferative diabetic retinopat
158 [NPDR], proliferative DR [PDR], or diabetic macular edema [DME]) or "any DR" (further subclassified
159 age-related macular degeneration or diabetic macular edema does not respond to an initial anti-vascul
160 age-related macular degeneration or diabetic macular edema does not respond to an initial anti-vascul
161 nited States, and included 362 patients with macular edema due to central retinal or hemiretinal vein
163 d safety of aflibercept for the treatment of macular edema due to central retinal vein occlusion.
165 th Intravitreal Aflibercept in Subjects with Macular Edema Due to Retinal Vein Occlusion (TANZANITE)
166 s not alter choroidal thickness in eyes with macular edema due to RVO, but may result in expansion of
167 38 eyes of 38 treatment-naive patients with macular edema due to RVO, enrolled in the prospective Su
169 5 pregnant women who presented with diabetic macular edema during pregnancy in the period from 2011 t
170 e processes, including postoperative cystoid macular edema, epiretinal membrane formation, macular fo
171 uring the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) A and B Phase III clinical trials.
172 ts with vision loss in 1 eye attributable to macular edema following BRVO were recruited from 5 insti
173 of ranibizumab in the treatment of diabetic macular edema has been proven with large clinical trials
174 nterval {CI}, 2.15-4.35], P < .001), cystoid macular edema (HR = 2.87 [95% CI, 1.41-5.82], P = .004),
175 % CI, 0.99-3.17], P = .06), the incidence of macular edema (HR, 1.04 [95% CI, 0.83-1.29], P = .74; OR
179 ty, central subfield thickness, and rates of macular edema improvement (>20% reduction in central sub
180 atment groups in the proportion of eyes with macular edema improving (systemic therapy vs. implant, 6
183 age-related macular degeneration or diabetic macular edema in a 9-member retinal specialty private pr
185 ly on central subfield thickness to quantify macular edema in central and branch retinal vein occlusi
187 gnosis of cystoid macular edema or new-onset macular edema in patients with diabetes, recorded by a h
188 abetic retinopathy or clinically significant macular edema in patients with various initial retinopat
193 nges that were hyperautofluorescent, cystoid macular edema in the inner nuclear layer, no light rise
195 te key clinical observations of ischemia and macular edema in the posterior pole and ischemia in the
196 he initial DEX implant, the mean duration of macular edema in treatment-naive patients was 4.9 months
197 wn to prevent the recurrence or worsening of macular edema in uveitic patients with a history of CME
200 ults (mean age, 61+/-10 years) with diabetic macular edema involving the macular center to receive in
207 litis and low-grade vitritis with or without macular edema may have birdshot chorioretinopathy eviden
209 fficacy variables were: patients (%) in whom macular edema (ME) developed (>/=30% increase from preop
212 erapeutic alternatives for the management of macular edema (ME) secondary to branch retinal vein occl
213 cteristic retinal vascular lesions including macular edema (ME), a leading cause of vision loss in DR
217 phthalmoscopic examination features included macular edema, mild intraretinal pigment migration, and
219 53 and/or presence of clinically significant macular edema; n = 95) using the modified Airlie House c
220 cident proliferative diabetic retinopathy or macular edema, nor of statin use with decreased incidenc
221 e not associated with clinically significant macular edema (NPA, P = 0.99; NPI, P = 0.67), nor correl
226 presence of morphologic features of diabetic macular edema on Spectralis optical coherence tomography
228 Patients with a history of retinopathy and macular edema or a current diagnosis indicating ophthalm
229 x implant whenever there was a recurrence of macular edema or a decrease in best-corrected visual acu
230 ical susceptibility to postoperative cystoid macular edema or exacerbation of choroidal neovasculariz
232 low-density lipoprotein and the incidence of macular edema or the worsening of diabetic retinopathy i
235 abetic retinopathy or worse, the presence of macular edema, or an unable-to-determine result for reti
236 rse diabetic retinopathy, referable diabetic macular edema, or both, were generated based on the refe
239 y significantly reduced rates of OCT-evident macular edema (P = 0.045) and clinically evident radiati
240 15), retinal detachments (P = 0.76), cystoid macular edema (P = 0.83), or timing of complications bet
242 n for the prevention of pseudophakic cystoid macular edema (PCME) using a prospective, randomized, do
244 e best-corrected visual acuity, incidence of macular edema, posterior capsular opacification, epireti
246 rovement can continue in some patients after macular edema resolves and CFT decreases stabilize.
247 changes in BCVA from baseline at 2 years by macular edema response status were: resolution, +10 lett
248 nstrated that VEGF is a major contributor to macular edema resulting from retinal vein occlusion, als
250 control, worsening of visual acuity, cystoid macular edema, retroprosthetic membrane formation, persi
252 f DEX implant treatment in 289 patients with macular edema secondary to branch or central RVO (BRVO,
253 ia in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion
254 inferior to aflibercept for the treatment of macular edema secondary to central retinal or hemiretina
255 led observational case study of 30 eyes with macular edema secondary to central retinal vein occlusio
256 Questionnaire (NEI VFQ-25), in patients with macular edema secondary to central retinal vein occlusio
257 gain in a broad population of patients with macular edema secondary to CRVO, including those with ma
258 cutive case study of patients with recurrent macular edema secondary to either central or branch reti
259 nd safety of DEX implant in the treatment of macular edema secondary to retinal vein occlusion (RVO)
263 ing DR was defined as clinically significant macular edema, severe nonproliferative DR, or proliferat
264 ired blood-retinal barrier function leads to macular edema that is closely associated with the deteri
265 monstrated modest improvements in vision and macular edema that warrant additional investigation of t
266 the prognostic significance of postoperative macular edema, the role of prophylaxis, the risk among b
268 and mean number of months from diagnosis of macular edema to randomization was 6 (range, 0-104 month
271 raded centrally for retinopathy severity and macular edema using the Early Treatment Diabetic Retinop
273 abetic retinopathy or clinically significant macular edema was 1.0% over 5 years among patients with
276 oth central and branch occlusions, recurrent macular edema was detected in non-central macular fields
278 abetic retinopathy or clinically significant macular edema was limited to approximately 5% between re
281 .001]), whereas an increased risk of cystoid macular edema was not identified for those who received
282 % CI, 3.0%-6.4%), and clinically significant macular edema was observed among 2.0% (95% CI, 1.1%-3.3%
286 which is increased in patients with diabetic macular edema, was capable of cleaving netrin-1 into the
287 sed by multiadjusted odds of retinal cystoid macular edema, was not increased for patients receiving
290 undred four eyes of 77 patients with uveitic macular edema were identified at a tertiary care center.
294 20/40(+2), except in 1 patient with cystoid macular edema whose vision was 20/60(-) and 20/70(+1).
296 ith PA alone, the OR for the relationship of macular edema with PA+NSAID was 0.45 (95% CI, 0.21-0.95)
298 and efficacy of treatment of RVO-associated macular edema with sequential DEX implants in clinical p
299 atment was associated with a reduced risk of macular edema with visual acuity of 20/40 or worse.
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。